史录文/管晓东团队在中国抗肿瘤新药临床试验对照组评价中取得进展

中国药学(英文版) ›› 2024, Vol. 33 ›› Issue (1): 69-71.

史录文/管晓东团队在中国抗肿瘤新药临床试验对照组评价中取得进展

北京大学药学院药事管理与临床药学系

北京大学药学院药事管理与临床药学系

收稿日期:2024-01-18 修回日期:2024-01-18 接受日期:2024-01-18 出版日期:2024-01-31 发布日期:2024-03-03

The team of Prof. Luwen Shi and Prof. Xiaodong Guan made progress in randomized clinical trials of investigational cancer drugs in China

Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center

Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center

Received:2024-01-18 Revised:2024-01-18 Accepted:2024-01-18 Online:2024-01-31 Published:2024-03-03

摘要/Abstract

摘要：

2023年12月12日, 北京大学药学院药事管理与临床药学系史录文/管晓东团队在医学权威期刊PLOS Medicine在线发表了题为“Use of Suboptimal Control Arms in Randomized Clinical Trials of Investigational Cancer Drugs in China, 2016-2021: An Observational Study”的研究成果。该文基于国内外肿瘤学指南与临床实践, 对2016-2021年中国登记的抗肿瘤新药随机试验的对照组质量进行了全面评价。

Supporting:

北京大学药学院药事管理与临床药学系. 史录文/管晓东团队在中国抗肿瘤新药临床试验对照组评价中取得进展[J]. 中国药学(英文版), 2024, 33(1): 69-71.

Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center. The team of Prof. Luwen Shi and Prof. Xiaodong Guan made progress in randomized clinical trials of investigational cancer drugs in China[J]. Journal of Chinese Pharmaceutical Sciences, 2024, 33(1): 69-71.